Home > Publications Database > Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series. > print

001     276151
005     20250209000709.0
024 7 _ |a 10.3389/fnins.2024.1505999
|2 doi
024 7 _ |a pmid:39834700
|2 pmid
024 7 _ |a pmc:PMC11744071
|2 pmc
024 7 _ |a 1662-4548
|2 ISSN
024 7 _ |a 1662-453X
|2 ISSN
024 7 _ |a altmetric:173200005
|2 altmetric
037 _ _ |a DZNE-2025-00223
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wagemann, Olivia
|0 P:(DE-2719)9001249
|b 0
|e First author
|u dzne
245 _ _ |a Feasibility and potential diagnostic value of [18F]PI-2620 PET in patients with down syndrome and Alzheimer's disease: a case series.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738668857_12998
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Adults with Down Syndrome (DS) have a substantially increased risk for Alzheimer's disease (AD) due to the triplicated amyloid-precursor-protein gene on chromosome 21, resulting in amyloid and tau accumulation. However, tau PET assessments are not sufficiently implemented in DS-AD research or clinical work-up, and second-generation tau tracers such as [18F]PI-2620 have not been thoroughly characterized in adults with DS. We aim at illustrating feasibility and potential diagnostic value of tau PET imaging with [18F]PI-2620 for the diagnosis of DS-AD.Five adults with DS (40% female, aged 43-62) and cognitive decline underwent clinical assessments, neuropsychological testing, lumbar puncture and multimodal neuroimaging. All underwent [18F]PI-2620 tau PET. Visual read of tau PET scans was performed by three blinded raters, assessing increased tracer uptake in brain areas corresponding to the six Braak stage regions and basal ganglia.Visual read of tau burden revealed three tau-positive individuals which corresponded to their clinical decline while two cognitively stable individuals were rated as negative. Rating showed high inter-rater reliability for all Braak stages.Tau PET imaging is a feasible and important biomarker assessment in the differential diagnosis of cognitive decline in adults with DS at risk of developing AD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a 18F-PI-2620
|2 Other
650 _ 7 |a Alzheimer
|2 Other
650 _ 7 |a case series
|2 Other
650 _ 7 |a down syndrome
|2 Other
650 _ 7 |a tau PET
|2 Other
650 _ 7 |a trisomy 21
|2 Other
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 1
|u dzne
700 1 _ |a Franzmeier, Nicolai
|b 2
700 1 _ |a Nübling, Georg
|0 P:(DE-2719)9001761
|b 3
|u dzne
700 1 _ |a Gnoerich, Johannes
|0 P:(DE-2719)9001652
|b 4
|u dzne
700 1 _ |a Zaganjori, Mirlind
|b 5
700 1 _ |a Prix, Catharina
|0 P:(DE-2719)9001508
|b 6
|u dzne
700 1 _ |a Stockbauer, Anna
|0 P:(DE-2719)9002610
|b 7
|u dzne
700 1 _ |a Wlasich, Elisabeth
|b 8
700 1 _ |a Loosli, Sandra V
|b 9
700 1 _ |a Sandkühler, Katja
|b 10
700 1 _ |a Frontzkowski, Lukas
|b 11
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 12
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 13
|e Last author
|u dzne
773 _ _ |a 10.3389/fnins.2024.1505999
|g Vol. 18, p. 1505999
|0 PERI:(DE-600)2411902-7
|p 1505999
|t Frontiers in neuroscience
|v 18
|y 2025
|x 1662-4548
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276151/files/DZNE-2025-00223.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276151/files/DZNE-2025-00223.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276151
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001249
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001539
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001761
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)9001652
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 6
|6 P:(DE-2719)9001508
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9002610
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2811659
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROSCI-SWITZ : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-11-09T08:11:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-11-09T08:11:26Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-11-09T08:11:26Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110008
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21